TerminatedPhase 1NCT03462004
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Kawsar Talaat, MDJohns Hopkins Bloomberg School of Public Health
- Intervention
- HPIV3/ΔHNF/EbovZ GP vaccine(biological)
- Enrollment
- 15 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2018 – 2019
Study locations (2)
- Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
- CIR Inpatient Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03462004 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University